EUVIMEDEUVIMED entdecken
Open Access

Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA

May Hagiwara, Victoria Divino, Swapna Munnangi, Mark Delegge, Suna Park, Ed G Marins, Kaili Ren, Charlie Strange

Journal of Comparative Effectiveness Research · 2024

DOI: 10.57264/cer-2023-0186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von May Hagiwara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, Cambridge, MA 02421, USA. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Liver Diseases, Lung Diseases. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate all-cause and liver-associated healthcare resource utilization (HCRU) and costs among patients with alpha-1 antitrypsin deficiency (AATD) with liver disease (LD) and/or lung disease (LgD). Materials & methods: This was a retrospective analysis of linked administrative claims data from the IQVIA PharMetrics ® Plus and the IQVIA Ambulatory Electronic Medical Records (AEMR) databases from 1 July 2021 to 31 January 2022. Patients with AATD in the IQVIA PharMetrics Plus database were included with ≥1 inpatient or ≥2 outpatient medical claims ≥90 days apart with a diagnosis of AATD, or with records indicating a protease inhibitor (Pi)*ZZ/Pi*MZ genotype in the IQVIA AEMR database with linkage to IQVIA PharMetrics Plus. For a patient's identified continuous enrollment period, patient time was assigned to health states based on the initial encounter with an LD/LgD diagnosis. A unique index date was defined for each health state, and HCRU and costs were calculated per person-year (PPY).

Results

Overall, 5136 adult and pediatric patients from the IQVIA PharMetrics Plus and IQVIA AEMR databases were analyzed. All-cause and liver-associated HCRU and costs were substantially higher following onset of LD/LgD. All-cause cost PPY ranged from US $11,877 in the absence of either LD/LgD to US $74,015 in the presence of both LD and LgD. Among liver transplant recipients in the AATD with LD health state, liver-associated total costs PPY were US $87,329 1-year pre-transplantation and US $461,752 1-year post-transplantation. In the AATD with LgD and AATD with LD and LgD health states, patients who received augmentation therapy were associated with higher all-cause total costs PPY and lower liver-associated total costs PPY than their counterparts who did not receive augmentation therapy.

Conclusion

Patients with AATD had increased HCRU and healthcare costs in the presence of LD and/or LgD. HCRU and healthcare costs were highest in the AATD with LD and LgD health state.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-Antitrypsin DeficiencyLiver DiseasesLung DiseasesHumansRetrospective StudiesMaleFemaleMiddle AgedUnited StatesAdultLongitudinal StudiesPatient Acceptance of Health CareHealth Care CostsAgedYoung AdultAdolescentHealth Resources

Stichwörter der Autor:innen

alpha-1 antitrypsin deficiencyclaims datacostshealthcare resource utilizationliver diseaselung disease

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, Cambridge, MA 02421, USA.
  • IQVIA Inc., 3110 Fairview Park, Falls Church, VA 22042, USA.
  • Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA.

Zitieren

APA

Hagiwara, M., Divino, V., Munnangi, S., Delegge, M., Park, S., Marins, E. G., Ren, K., & Strange, C. (2024). Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0186

Vancouver

Hagiwara M, Divino V, Munnangi S, Delegge M, Park S, Marins EG, et al. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2023-0186

BibTeX
@article{Hagiwara2024,
  author = {Hagiwara, May and Divino, Victoria and Munnangi, Swapna and Delegge, Mark and Park, Suna and Marins, Ed G and Ren, Kaili and Strange, Charlie},
  title = {Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2024},
  doi = {10.57264/cer-2023-0186}
}
Kostenlos starten →